Iatrogenic Cushing's syndrome induced by posaconazole

Antimicrob Agents Chemother. 2013 Nov;57(11):5727-8. doi: 10.1128/AAC.00416-13. Epub 2013 Aug 26.

Abstract

Iatrogenic Cushing's syndrome is an undesirable outcome of glucocorticoids treatment. It can be increased by pharmacologic interactions. Glucocorticoid therapy, given in association with ritonavir, and some azole treatments are causes of iatrogenic Cushing's syndrome. We present a patient with common-variable immunodeficiency who received 7 years of itraconazole therapy for bronchial colonization with Aspergillus in combination with inhaled fluticasone without any Cushingoid symptoms. After a switch to posaconazole, the patient developed Cushingoid symptoms.

Publication types

  • Case Reports

MeSH terms

  • Androstadienes / adverse effects*
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / complications
  • Aspergillosis / drug therapy
  • Aspergillosis / immunology
  • Aspergillosis / microbiology
  • Bronchi / drug effects
  • Bronchi / immunology
  • Bronchi / microbiology
  • Bronchodilator Agents / adverse effects*
  • Common Variable Immunodeficiency / complications
  • Common Variable Immunodeficiency / drug therapy
  • Common Variable Immunodeficiency / immunology
  • Common Variable Immunodeficiency / microbiology
  • Cushing Syndrome / chemically induced*
  • Cushing Syndrome / physiopathology
  • Female
  • Fluticasone
  • Humans
  • Iatrogenic Disease
  • Itraconazole / therapeutic use*
  • Middle Aged
  • Triazoles / adverse effects*

Substances

  • Androstadienes
  • Antifungal Agents
  • Bronchodilator Agents
  • Triazoles
  • Itraconazole
  • posaconazole
  • Fluticasone